Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
OMN-6
- Development stage
- Phase 2
- Lead developer
- Omnix Medical
- Modality
- Antimicrobial Peptides → Native Peptides → Peptides, Cyclic Peptides → Modified Peptides → Peptides, Small Molecules
- Administration
- Intravenous
01
Overview
OMN-6 is a novel, first-in-class antimicrobial peptide (AMP) developed by Omnix Medical for the treatment of life-threatening infections caused by multi-drug resistant Gram-negative bacteria, including *Acinetobacter baumannii* complex. The drug is based on insect host defense peptides and has been optimized using proprietary technology to enhance efficacy, potency, safety, and stability while maintaining bioactivity. Its mechanism of action involves rapid bactericidal activity through physical disruption of bacterial cell membranes—a mode that is effective regardless of bacterial genotype or resistance phenotype and avoids common mechanisms of antimicrobial resistance. OMN-6 has demonstrated potent *in vitro* and *in vivo* activity against both susceptible and drug-resistant Gram-negative bacteria with no observable cross-resistance or toxicity toward mammalian cells. It is currently being evaluated in Phase II clinical trials for hospital-acquired bacterial pneumonia (HABP) and ventilator-associated bacterial pneumonia (VABP)[1][2][3][4][5][8].
- Other names
- OMN6OMN-6OMN 6
02
Targets
OMP (Bacterial outer membrane protein)
Beyond the preview
Go deeper on OMN-6.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on OMN-6.